Treatment Recommendations for Low-Risk Prostate Cancer

Risk Stratification

The National Comprehensive Cancer Network recommends that patients with Gleason 3+3 prostate cancer be considered low-risk, despite a PSA of 15 ng/mL, as the Gleason score is the most important prognostic factor 2
A PSA of 15 ng/mL exceeds the typical low-risk threshold of 10 ng/mL, placing this patient in the intermediate-risk category, but with a favorable Gleason score, it represents a case of "favorable intermediate-risk" prostate cancer 2, 3

The National Comprehensive Cancer Network recommends active surveillance as the preferred approach for low-risk prostate cancer and selected favorable intermediate-risk cases, as it avoids unnecessary treatment side effects while maintaining excellent cancer-specific survival rates 2, 5
Active surveillance benefits include avoiding side effects of definitive therapy, maintaining quality of life, and avoiding overtreatment of indolent cancers 1, 6
The Canadian protocol for active surveillance includes PSA testing and digital rectal examination every 3 months for 2 years, then every 6 months, and prostate biopsies at 1 year and then every 3-4 years 5, 7

The Journal of Urology suggests that surgery is an option for patients with intermediate-risk disease and life expectancy >10 years, with potential complications including erectile dysfunction and urinary incontinence 7

The National Comprehensive Cancer Network recommends external beam radiation therapy as an effective option, with a minimum dose of 70 Gy, and brachytherapy alone can be considered for patients with favorable intermediate-risk disease 8, 9

The National Comprehensive Cancer Network recommends PSA testing every 3-6 months, digital rectal examination at least annually, confirmatory biopsy within 6-12 months of diagnosis, and subsequent biopsies every 1-3 years 1, 5, 7

The National Comprehensive Cancer Network recommends intervention for Gleason grade progression, PSA doubling time less than 3 years, increase in number or extent of positive biopsy cores, and clinical progression on examination 1, 5, 6

The National Comprehensive Cancer Network notes that despite the elevated PSA, the Gleason 3+3 histology is the most important prognostic factor, indicating a very low risk of disease progression 2
Patients must understand that PSA may rise and tumor may grow with time, necessitating regular monitoring and potential future intervention 1, 6